Therapeutic strategies for epidemic Kaposi's sarcoma

International Journal of STD and AIDS

Volumn 17, Issue 9, 2006, Pages 571-578

  Aldenhoven, M ^a   Barlo, N P ^a   Sanders, C J G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

AIDS; Kaposi; Sarcoma; Therapeutics; Therapy

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BLEOMYCIN; CHORIONIC GONADOTROPIN; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IM 862; INTERSTITIAL COLLAGENASE; PACLITAXEL; PROTEINASE INHIBITOR; RETINOID; RNA DIRECTED DNA POLYMERASE INHIBITOR; THALIDOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANEMIA; CANCER INCIDENCE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CRYOTHERAPY; DEPRESSION; EPIDEMIC; FATIGUE; FEVER; GENE THERAPY; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERPIGMENTATION; IRRADIATION; KAPOSI SARCOMA; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RASH; REVIEW; RNA INTERFERENCE; THROMBOCYTOPENIA; VOMITING;

HUMANS; INCIDENCE; SARCOMA, KAPOSI;

EID: 33748356309     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206778113131     Document Type: Review

References (67)

1. Kaposi M. Idiopatisches multiples Pigmentsarkom der Haut. Arch Dermatol Syphilis 1872;4:265-73
2. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982;96:693-700
3. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989;7:1201-7
4. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003;21:2876-82
5. Sanders CJ. Kaposi's sarcoma in retrospect. Genitourin Med 1997;73:571-4
6. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9
7. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004;100:2644-54
8. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004;22:399-402
9. Nasti G, Martellotta F, Berretta M, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003;98:2440-6
10. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001;19:3848-51
11. Tam HK, Zhang ZF, Jacobson LP, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002;98:916-22
12. Cattelan AM, Calabro ML, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001;28:44-9
13. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 2000;14:987-93
14. Sanders CJ, Canninga-van Dijk MR, Borleffs JC. Kaposi's sarcoma. Lancet 2004;364:1549-52
15. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-5
16. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80
17. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:34-8
18. Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am 2003;17:763-83
19. Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother Oncol 1998;46:19-22
20. Yildiz F, Ozyar E, Uzal D, Sahin S, Atahan IL. Kaposi's sarcoma: the efficacy of a single fraction of 800 cGy. Dermatology 1997;195:142-4
21. de Wit R, Smit WG, Veenhof KH, Bakker PJ, Oldenburger F, Gonzalez DG. Palliative radiation therapy for AIDS-related Kaposi's sarcoma by using a single fraction of 800 cGy. Radiother Oncol 1990;19:131-6
22. Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993;28:61-5
23. Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001;2:77-87
24. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol 2000;136:1461-9
25. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999;22:235-46
26. Bernstein ZP, Wilson BD, Oseroff AR, et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS 1999;13:1697-704
27. Marchell N, Alster TS. Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser. Dermatol Surg 1997;23:973-5
28. Tappero JW, Grekin RC, Zanelli GA, Berger TG. Pulsed-dye laser therapy for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1992;27:526-30
29. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 1991;4:839-846
30. Lunardi-Iskandar Y, Bryant JL, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995;375:64-8
31. Gill PS, Lunardi-Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9
32. Tavio M, Nasti G, Simonelli C, et al. Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma. Eur J Cancer 1998;34:1634-7
33. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55
34. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988;2:1218-22
35. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6
36. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-51
37. Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374-81
38. Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998;16:1736-1742
39. Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379-84
40. Kovacs JA, Deyton L, Davey R, et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:280-7
41. Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:812-21
42. Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991;9:802-8
43. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48
44. Lynen L, Zolfo M, Huyst V, et al. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART. AIDS Rev 2005;7:13-21
45. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005;113:632-9
46. Tavio M, Vaccher E, Antinori A, et al. Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma. Cancer 1996;77:2117-22
47. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000;18:1550-7
48. Sprinz E, Caldas AP, Mans DR, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001;24:177-84
49. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64
50. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-91
51. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51
52. Osoba D, Northfelt DW, Budd DW, Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 2001;19:573-80
53. Mitsuyasu RT, von Roenn J, Krown S, et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's Sarcoma (AIDS-KS): AIDS clinical trial group (ACTG) protocol 286. Proc Am Soc Clin Oncol 1997;16:55 (Abstract)
54. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-9
55. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-83
56. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-21
57. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95:147-54
58. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
59. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-755
60. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602
61. Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist 2000;5(Suppl 1):28-31
62. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001;7(Suppl 3):S120-8
63. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:716-23
64. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9
65. Morini M, Albini A, Lorusso G, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Therapy 2004;11:284-91
66. Zacchigna S, Zentilin L, Morini M, et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 2004;11:73-80
67. Godfrey A, Laman H, Boshoff C. RNA interference: a potential tool against Kaposi's sarcoma-associated herpesvirus. Curr Opin Infect Dis 2003;16:593-600